Guided Therapeutics (GTHP) Enterprise Value (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Enterprise Value for 16 consecutive years, with -$63000.0 as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 83.76% to -$63000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$63000.0 through Dec 2025, up 83.76% year-over-year, with the annual reading at -$63000.0 for FY2025, 83.76% up from the prior year.
- Enterprise Value hit -$63000.0 in Q4 2025 for Guided Therapeutics, up from -$87000.0 in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$63000.0 in Q4 2025 to a low of -$2.7 million in Q3 2022.
- Historically, Enterprise Value has averaged -$790150.0 across 5 years, with a median of -$566000.0 in 2021.
- Biggest five-year swings in Enterprise Value: crashed 5838.1% in 2021 and later skyrocketed 83.76% in 2025.
- Year by year, Enterprise Value stood at -$643000.0 in 2021, then crashed by 259.72% to -$2.3 million in 2022, then soared by 74.45% to -$591000.0 in 2023, then soared by 34.35% to -$388000.0 in 2024, then surged by 83.76% to -$63000.0 in 2025.
- Business Quant data shows Enterprise Value for GTHP at -$63000.0 in Q4 2025, -$87000.0 in Q3 2025, and -$185000.0 in Q2 2025.